胃癌患者血清肿瘤相关胰蛋白酶抑制剂水平与临床病理参数的关系。

The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer.

机构信息

Department of General Surgery, School of Medicine, University of Yuzuncu Yil, Van, Turkey.

出版信息

Eur Rev Med Pharmacol Sci. 2013 Nov;17(21):2923-8.

Abstract

BACKGROUND

Tumor-associated trypsin inhibitor (TATI) is expressed with trypsinogen in tumors. We studied the clinical-pathologic association and significance of preoperative serum levels of TATI in gastric cancer patients.

PATIENTS AND METHODS

Pre-treatment serum levels of TATI in patients with gastric cancer and healthy controls were analyzed by a specific enzyme-linked immunosorbent assay (ELISA).

RESULTS

Statistically significant differences were found in serum TATI levels between patients with gastric cancer and healthy controls (p < 0.0001). There was a significant relationship between the serum levels of TATI and clinicopathological parameters. However, serum levels of TATI were significantly higher in patients with an advanced T stage (T3) (p < 0.001), lymph node metastasis (p < 0.001) and an advanced TNM stage (stage III or IV; p < 0.001).

CONCLUSIONS

Our study suggests that TATI may be used to identify potentially high-risk groups of upper gastric carcinoma. Elevated level of TATI was associated with progressive disease or advanced stage.

摘要

背景

肿瘤相关胰蛋白酶抑制剂（TATI）与胰蛋白酶原一起在肿瘤中表达。我们研究了术前胃癌患者血清 TATI 水平与临床病理的关系及其意义。

方法

采用特定的酶联免疫吸附试验（ELISA）分析胃癌患者和健康对照者的术前血清 TATI 水平。

结果

胃癌患者与健康对照组血清 TATI 水平存在显著差异（p<0.0001）。血清 TATI 水平与临床病理参数之间存在显著关系。然而，T 分期（T3）较高（p<0.001）、淋巴结转移（p<0.001）和更晚期的 TNM 分期（III 期或 IV 期；p<0.001）的患者血清 TATI 水平显著升高。